

Nanomedicine: Nanotechnology, Biology, and Medicine xx (2014) xxx-xxx NANO-00925; No of Pages 9

Nanomedicine Nanotechnology, Biology, and Medicine

nanomedjournal.com

22

Challenges facing sterilization and depyrogenation of nanoparticles: Effects on structural stability and biomedical applications

Melissa A. Vetten, Msc^{a,b,*}, Clarence S. Yah, PhD^{c,d}, Tanusha Singh, PhD^{e, f}, Mary Gulumian, PhD^{a,b}

^aBiochemistry and Toxicology Section, National Institute for Occupational Health, National Health Laboratory Services, Johannesburg, South Africa

^bDepartment of Molecular Medicine and Haematology, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa

^dDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

^eImmunology and Microbiology Section, National Institute for Occupational Health, National Health Laboratory Services, Johannesburg, South Africa

^fDepartment of Immunology, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa

Received 11 December 2013; accepted 29 March 2014

12 Abstract

This review outlines and compares techniques that are currently available for the sterilization of nanoparticles and addresses the topic of endotoxin contamination. Several techniques are available for the removal of microbial contamination from nanoparticles developed for use in nanomedicine applications. These techniques include filtration, autoclaving and irradiation, as well as formaldehyde, ethylene oxide and gas plasma treatments. Of these sterilization methodologies, filtration may potentially remove microbial contamination without altering the physicochemical properties of the carrier nanoparticles, nor affecting their toxicity and functionality. However, no single process may be applied to all nanoparticle preparations and, therefore, it is recommended that each nanoparticle-drug system be validated on a case-by-case basis.

- 19 © 2014 Published by Elsevier Inc.
- 20 Key words: Nanoparticles; Sterilization; Endotoxin
- 21

013

10

11

The authors declare that there are no competing interests.

*Corresponding author at: Biochemistry and Toxicology Section, National Institute for Occupational Health, National Health Laboratory Services, Johannesburg, South Africa.

E-mail address: melissa.vetten@nioh.nhls.ac.za (M.A. Vetten).

Introduction

The unique physical and chemical properties of nanoparticles 23 Q2 (NPs) have resulted in substantial research being performed on 24 their potential applications in various fields including biology 25 and medicine. Nanomedicine applications include the develop- 26 ment of "lab-on-chip" technology in order to assess biomarkers, 27 drug and gene delivery, tissue engineering, and cancer therapy.^{1,2} 28 Any nanoparticle-drug based formulation requires the solvent to 29 be sterile and apyrogenic, in addition to being safe, non-toxic and 30 non-irritating for both in vitro and in vivo applications. The term 31 sterility refers to the absence of viable microorganisms that could 32 pose a risk when administered. The current accepted sterility 33 assurance level (SAL) is limited to 10^{-6} , that is to say not more 34 than one viable microorganism in one million parts of final product 35 is allowed.³ Manufacturers of medical devices are required to 36 ensure that their products meet established quality requirements 37 and specifications, including regulations regarding microbial 38 contamination. Potential sources of microbial contamination 39 during production of pharmaceutics include the raw materials, 40

Please cite this article as: Vetten M.A., et al., Challenges facing sterilization and depyrogenation of nanoparticles: Effects on structural stability and biomedical applications. *Nanomedicine: NBM* 2014;xx:1-9, http://dx.doi.org/10.1016/j.nano.2014.03.017

^cHuman Sciences Research Council, Newton Park, South Africa

Abbreviations: ⁶⁰Co, Cobalt-60; ¹³⁷Cs, Cesium-137; AuNPs, gold nanoparticles; β-CDC6, Amphiphilic β-cyclodextrin; Cu/LDPE, Copper/ low-density polyethylene; DLS, dynamic light scattering; e-beam, electron beam; EO, Ethylene oxide; EDS, Energy-dispersive spectroscopy; ESD, Emulsion Solvent Diffusion; FDA, Food and Drug Administration; FTIR, Fourier transform infrared; Hap, hydroxyapatite; HS, hydrothermal synthesis; IUDs, intrauterine devices; LAL, limulus amoebocyte lysate; LPS, LPS lipopolysaccharide; NP, nanoparticle; PBCA, poly(butyl cyanoacrylate); PBLG, poly(γ-benzyl-L-glutamate); PEC, poly(ε -caprolactone); PEG, poly (ethylene glycol); PEG-AuNPs, poly(ethylene glycol) coated gold nanoparticles; PLGA, poly(DL-lactide-co-glycolide); SAL, sterility assurance level; SLNs, solid lipid nanoparticles; TEM, transmission electron microscopy; TiO₂, titanium dioxide; tiopronin-AuNPs, tiopronin coated gold nanoparticles; UV-Vis, ultraviolet-visible; WCS, wet chemical synthesis.

ARTICLE IN PRESS

2

M.A. Vetten et al / Nanomedicine: Nanotechnology, Biology, and Medicine xx (2014) xxx-xxx

t1.1 Table 1

t1.2 Summary of the effects of filtration on nanoparticles.

Pore size of filter	Type of nanoparticle	Mean approximate size	Effect of sterilization on nanoparticle	Outcome of sterilization method	Authors
0.2 μm	Poly(ε-caprolactone) nanospheres	130 nm; 160-180 nm	No aggregation and no effect on the nanoparticle morphology	Not tested	7
0.22 μm	PEGylated poly(γ-benzyl-L-glutamate) nanoparticles	50 nm	No change in size or polydispersity index. Slight change in zeta potential.	No detectable growth of bacteria, yeast or fungi	8
0.22 μm	Polyester nanoparticles	sub 200 nm	No clogging of the membrane filters. No significant change in particle size and size distribution	No bacterial contamination	9
0.2 μm	Poly(DL-lactide-co-glycolide) nanospheres	200-300 nm 103-163 nm	Less than 10% of nanospheres passed through filter. 100-98% of nanospheres passed through filter.	Passed bacterial sterility test	12

41 equipment and processes used during production, in addition to the
42 facility and personnel.⁴

Potential contaminating microorganisms include bacteria, fungi 43 and mould; however the removal of endotoxins, the lipopolysac-44 charides in the cell membrane of Gram-negative bacteria, must also 45 be addressed. Magalhães and colleagues⁵ provided a review of 46 endotoxins and their removal from biological preparations. They 47 discussed the pathophysiological effects of endotoxins, as caused 48 49by activation of the immune system and release of proinflammatory mediators, which lead to endotoxin shock, tissue 5051 injury and sometimes death. Since the effects of endotoxin are related to the amount of endotoxin present, in the case of drug 5253 products, this would imply that the endotoxin limit would be dependent on the amount of drug product administered to the 54patient. The formula for the endotoxin limit provided by the 55Food and Drug Administration (FDA) is K/M; where K is 565.0 EU/kilogram, and M is the maximum recommended dose of 57product per kilogram of body weight administered in 1 h.⁶ 58

Although numerous well-established sterilization techniques 59exist, concerns have been raised regarding the adverse effects that 60 these techniques may have on the physicochemical characteristics 61 of the nanoparticles. A change in these characteristics could 62 potentially affect both the toxicity and the efficacy of the sterilized 63 nanoparticles. This paper reviews various sterilization methodol-64 ogies that have been assessed for the removal of microbial and 65 endotoxin contamination from nanoparticle preparations with the 66 aim of providing a possible recommendation on a suitable 67 methodology for nanomedicine production and sterilization. 68

Methodologies implemented for the sterilizationof nanoparticles

A literature survey of publications obtained from reputable journals shows that several conventionally used methodologies such as filtration, autoclaving, irradiation, as well as treatment with formaldehyde, ethylene oxide and gas plasma, have been implemented for the sterilization of nanoparticles.

76 Filtration

77 Sterile filtration is a commonly used method for the physical 78 removal of microorganisms from chemically and thermally sensitive liquids, through the use of 0.22 μ m membrane filters. 79 This technique has been shown to be widely applicable as it does 80 not appear to have any adverse effects on the nanoparticles 81 (Table 1). Poly(ϵ -caprolactone) (PEC) nanospheres of mean 82 diameter below 200 nm were successfully sterilized by filtration 83 with 0.2 μ m cellulose acetate membrane filters without alteration 84 of their size, morphology or concentration.⁷ Filter sterilization 85 through 0.22 μ m filters has also successfully been implemented 86 for the sterilization of PEGylated poly(γ -benzyl-L-glutamate) 87 (PBLG) NPs⁸ and polyester NPs.⁹ 88

The use of 0.2 μ m or 0.22 μ m filters may not always be possible ⁸⁹ if the NPs are larger than, or close to, the pore size of the filters since ⁹⁰ clogging can occur resulting in a decreased yield.^{10,11} For example, ⁹¹ filtration of 200-300 nm poly(DL-lactide-co-glycolide) (PLGA) ⁹² nanospheres prepared using the standard Emulsion Solvent ⁹³ Diffusion (ESD) method resulted in less than 10% of the ⁹⁴ nanospheres passing through the membrane filter.¹² This problem ⁹⁵ was circumvented by optimizing the synthesis methodology ⁹⁶ to produce nanospheres with a particle diameter of 103-163 nm, ⁹⁷ of which 100-98% could pass through the membrane filter and ⁹⁸ successfully pass bacterial sterility tests. However adjusting the ⁹⁹ size of the nanoparticles in order to enable them to pass through a ¹⁰⁰ membrane filter may not always be feasible.

Sterile filtration may therefore present itself as a reasonable 102 method for the removal of bacterial contamination, provided that 103 a sufficiently high percentage of nanoparticles can be recovered 104 following filtration. 105

106

Autoclaving

Autoclaving kills microbes with high pressurized steam, at 107 a minimum temperature of 121 °C, within 15-20 min depending 108 on the size of the load and the contents to be sterilized. This 109 methodology has been shown to have a number of effects on the 110 nanoparticles sterilized (Table 2). Fesharaki and colleagues 111 synthesized selenium nanoparticles using *Klebsiella pneumonia* 112 bacteria followed by recovery of the nanoparticles from the 113 bacteria by autoclaving at 121 °C, 17 psi for 20 min. Energy-114 dispersive spectroscopy (EDS) confirmed chemical stability 115 of the selenium nanoparticles before and after sterilization. ¹³ 116 On the other hand, autoclaving PBLG NPs at 121 °C for 20 min 117 resulted in the aggregation and a drastic increase in size of these 118 Download English Version:

https://daneshyari.com/en/article/10436075

Download Persian Version:

https://daneshyari.com/article/10436075

Daneshyari.com